Fosun Kite Biotechnology Co., Ltd.

PRINCETON, N.J., Nov. 28, 2023 /PRNewswire/ -- Fosun Pharma USA Inc. ("Fosun Pharma USA") announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer's (IASLC) 2023 North America Conference on Lung Cancer (NACLC), being held in Chicago, Illinois, Dec. 1 - 3, 2023. All abstracts accepted for presentation have been published on the NACLC website. "Our PIs are excited to present their poster on the design of the ASTRIDE Trial in Progress (TiP), which is an important milestone for the lead investigators and authors," said Stan Lechpammer, Vice President, Medical Affairs, Innovative Medicines, Fosun Pharma USA. "This presentation provides greater insight into the ASTRIDE trial that investigates serplulimab as a potentially new therapeutic option for extensive-stage (ES) small-cell lung cancer patients (SCLC). SCLC is an aggressive malignancy, with the majority of patients presenting with extensive-stage disease at initial diagnosis. There is a high unmet need for this patient population. Beyond the potential of our TiP study design, we have committed to recruiting patients from many medically underserved communities, to address health disparities and improve health equity for ES-SCLC patients in the U.S." Abstract accepted for presentation's details and key points about the study design: Key Highlights about Study Design Trial will include approximately 200 adult patients with treatment-naïve ES-SCLC Study participants are being recruited from over 90 sites across the United States About Serplulimab Serplulimab is a novel anti–PD-1 (programmed cell death-1) monoclonal antibody (mAb), with a unique mode of recognition of the PD-1 receptor compared with currently available anti–PD-1 mAbs (Issafras et al. Plos One. 2021). About the ASTRIDE Phase 3 Trial ASTRIDE is a randomized, open-label study of serplulimab plus chemotherapy (carboplatin-etoposide) compared with atezolizumab plus chemotherapy in previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC) in the United States. The primary objective for ASTRIDE is to confirm the applicability of the results of ASTRUM-005 (a global, randomized, phase 3 trial) to patients in the United States, with the current standard-of-care as the control arm, based on comments from the U.S. Food and Drug Administration (Serplulimab study protocol 2.0 final. Shanghai Henlius Biotech, Inc.; July 18, 2022). About Small-cell Lung Cancer Approximately 30,000-35,000 people are diagnosed with small-cell lung cancer (SCLC) each year in the United States. It is the most aggressive form of lung cancer with approximately 70% of patients presenting with extensive-stage disease (ES-SCLC), with a median overall survival of approximately 12.5 months with standard-of-care treatment. About Fosun Pharma USA Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharma (Group) co., Ltd. Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun HQ"). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven, pharmaceutical and healthcare industry group. Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need. Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products. The company is continuing to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products for the U.S. market, primarily. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: ; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc. Fosun Pharma USA Forward-Looking Statement This presentation may include predictions, estimates, current target dates, current target indications, current plans, or other information (hereinafter "prospective information") that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions as to said prospective information only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information, developments, changed circumstances, or future events. During today's discussion, we will attempt to present some important factors relating to our business that may affect our aforementioned prospective information. Fosun Pharma USA Contacts: Media or Investors: Lucia Allen Chau Director of Public Relations & Communications +1 (484) 636-6105 [email protected] SOURCE Fosun Pharma USA

NEW YORK and LONDON, Nov. 20, 2023 /PRNewswire/ -- Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies. The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market. There will also be a high degree of focus on high quality non-U.S. clinical stage biopharma assets, seeking to access the U.S. market. Continue Reading Fosun Pharma USA and Treehill Partners combine forces The investment team's strategy will focus on opportunities where a combination of capital, senior leadership involvement and product development acumen will present the key to unlocking value in a short or mid timeframe. "Over the recent quarters we have observed a tendency of stand-still in the industry resulting from limited capital being available for biotech product development. This has left a large number of programs unable to advance and ultimately reach patients, not only because clinical activities could not take place due to insufficient funding, but also because companies were not able to attract the expertise necessary to move forward successfully," Rong Yang, CEO, Fosun Pharma USA, said. "We are combining forces with Treehill Partners given their proven track record with end-to-end capabilities bridging across corporate and product development." The business, jointly led by Rong Yang and Ali Pashazadeh (CEO and co-founder, Treehill Partners), will be seeking to make its first investments during 2024. The full spectrum of activities along the investment life cycle — from strategy creation, target identification and investment, over product and business development, to value realization and strategic exit options, will be jointly managed. "This strategic step is the start of a new chapter in the growth journey of Fosun Pharma USA. Recently, we have built a detailed understanding of the landscape of opportunities and pathways for value creation in this market, which we are looking to pursue actively in an innovative structure," Yang added. "We look forward to working with the CEOs and leadership teams of our future portfolio companies on a mission to commercialize innovative products that address significant needs of patients worldwide." "We have selected Fosun as a preeminent global partner who shares our work ethos and vision for novel pathways of biopharma product development, with whom we have established a trustful relationship over many years," Pashazadeh said. As the companies and assets in the investment portfolio mature, the partners will be looking to source third-party capital in several possible structures that will be decided on a case-by-case basis. About Fosun Pharma USA Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharma (Group) co., Ltd. Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun HQ"). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven, pharmaceutical and healthcare industry group. Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need. Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products. The company is continuing to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products for the U.S. market, primarily. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: ; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc. Fosun Pharma USA Contacts: Media or Investors: Lucia Allen Chau Director of Public Relations & Communications +1 (484) 636-6105 [email protected] About Treehill Partners Treehill Partners is an international strategic and financial advisory firm exclusively focused on the healthcare sector. Its multidisciplinary team offers actionable strategic and transaction advice to healthcare CEOs, leadership teams, stakeholders, and investors, with a focus on value-creating transactions and successful corporate evolution strategies. To learn more about Treehill Partners, visit . For more information please contact: [email protected] SOURCE Fosun Pharma USA

HONG KONG, Nov. 17, 2023 /PRNewswire/ -- On 9 November 2023, the TVB ESG Awards 2023 (the "Awards"), organized by Television Broadcasts Limited ("TVB") was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with "Best in ESG Practices" and "Best in ESG Report" at the Awards. Mr. Michael Wong, Deputy Financial Secretary of the Hong Kong Special Administrative Region (SAR), Dr. the Honorable Lam Ching-choi, a non-official member of the Executive Council of the Hong Kong SAR and Chairman of the Council for Carbon Neutrality & Sustainable Development, served as officiating guests and delivered speeches at the Awards. Evaluated by a professional judging panel based on various aspects, the Awards aims to select industry leaders who have demonstrated outstanding performance in ESG and sustainable development. TVB pointed out that Fosun International is a deserving winner of the "Best in ESG Practices" and "Best in ESG Report". Fosun International has complied well with the disclosure requirements from the Hong Kong Stock Exchange and made reference to other reporting standards such as the Global Reporting Initiative (GRI) Standards, the Task Force on Climate-related Financial Disclosures (TCFD) recommendations and the Sustainable Development Goals (SDGs). In addition, Fosun International ESG Report not only demonstrated Fosun's business-focused strategy, it also well elaborated how Fosun has been adhering to the original aspiration of "Contribution to Society". In the course of continuous development, Fosun has leveraged its increasingly sophisticated industrial ecosystem to actively contribute to people's livelihood and public welfare worldwide. Fosun joins hands with its global industrial ecosystem to promote sustainability globally After over 30 years of development, Fosun has grown into a global innovation-driven consumer group with a focus on Health, Happiness, Wealth and other business segments in more than 35 countries and regions. While growing its business operations, Fosun has been also actively undertaking corporate social responsibility. Leveraging Fosun's global industrial ecosystem to achieve "multiplying growth", the Group is dedicated to creating a better world. As a responsible global citizen, Fosun has continued to strengthen sustainable development management, implement and monitor Fosun's ESG strategies and targets. Fosun joined the United Nations (UN) Global Compact in 2014 and is committed to the global commitment of sustainable development. The Group fully supports the ten principles of the UN Global Compact in the fields of human rights, labor, environment, anti-corruption, etc., continuously promotes their close integration with its own ESG strategies and actively engages its member companies in the implementation of ESG strategies. Fosun has incorporated "Business for Good" into the "global organization + local operations" business model. As a result, "Business for Good" has been tightly combined with the cross-regional, cross-cultural and cross-organizational operational capability in Fosun's global industrial ecosystem. On the one hand, Fosun has introduced overseas enterprises with excellent ESG practices into China. With the local operational capabilities accumulated over years, Fosun reenergized sustainable products and services and promoted the ecological transition and the replacement of sustainable consumption and production patterns in China. On the other hand, relying on the global operational capabilities, Fosun has also brought the world innovative technologies, quality products and best ESG practices of various countries, including China, with a view to creating happier lives for families worldwide. Taking Artesun® (artesunate for injection) innovated and self-developed by Fosun Pharma as an example, Artesun® is the preferred treatment of severe malaria recommended by the World Health Organization (WHO). It has become a well-known Chinese innovator drug in Africa and the world. So far, Artesun® has been used to treat more than 60 million patients with severe malaria worldwide, most of whom were African children under five years old. In June 2023, the second-generation artesunate for injection Argesun® independently developed by Fosun Pharma was prequalified by the WHO prequalification (WHO-PQ), becoming the first injectable artesunate presented with a single solvent system with the WHO-PQ, which is expected to further enhance the accessibility of innovative antimalarial drugs and save more lives. Domestically, Fosun Foundation launched the Rural Doctors Program in 2017. As of today, the Rural Doctors Program has covered 78 counties in 16 provinces, municipalities, and autonomous regions across China, supporting 23,956 rural doctors and benefiting 3 million grassroots families. In addition to Fosun International, award recipients of the"Best in ESG Practices" and "Best in ESG Report" include Hong Kong well-known companies such as MTR Corporation, Link REIT, Henderson Land Development, Sino Land, and NWS Holdings. SOURCE Fosun